Anti-C1q in systemic lupus erythematosus

Research output: Contribution to journalArticle


C1q is the first component of the classical complement pathway. Both clinically validated in-house ELISA assays as well as commercial ELISA kits are used for detection of anti-C1q antibodies. Anti-C1q autoantibodies can be detected in a wide range of autoimmune diseases and are highly sensitive for hypocomplementemic uticarial vasculitis. In SLE, anti-C1q are strongly associated with proliferative lupus nephritis, and their absence carries a negative predictive value for development of lupus nephritis of close to 100%. Anti-C1q in combination with anti-dsDNA and low complement has the strongest serological association with renal involvement. The anti-C1q titers correlate with global disease activity scores in patients with renal involvement, and higher titers seem to precede renal flares. After the successful treatment of a renal flare, anti-C1q has the tendency to decrease or even become undetectable. The main obstacle to the inclusion of anti-C1q in the classification criteria and clinical management of SLE is the lack of standardized laboratory assays.

Original languageEnglish (US)
Pages (from-to)873-877
Number of pages5
Issue number8
Publication statusPublished - Jul 1 2016



  • anti-C1q
  • C1q
  • lupus nephritis
  • SLE
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this